Medical network - on February 10, the spring comes, the weather gets warmer, indoors suppressed people out of their homes, the winter outdoor activities. But note that in addition to the spring blossoms and revival, and high incidence of respiratory diseases. Spring in the air, the content of pollen, bacteria, viruses and other allergens and flow increased significantly, the allergens is important inducing factors of asthma and other respiratory diseases.
The full name of asthma bronchial asthma, it is by a variety of cells and cell components involved in chronic airway inflammation, often lead to recurrent wheezing, shortness of breath, chest tightness and (or) symptoms such as cough, seriously affect the patients study, work and life. It is estimated that about 30 million asthma patients in our country, the mortality rate of 36.7/10, far higher than the developed countries.
Divided into the control of asthma drugs drugs and ease. The former role in asthma remission, the main treatment of bronchial airway chronic inflammation, such as inhaled corticosteroids, leukotriene regulator, long-acting beta 2 agonists, theophylline and so on; The latter effect on asthma episodes, by rapidly relieve bronchial spasms and relieve asthma symptoms, such as short-acting beta 2 agonists, a short-acting inhaled anticholinergic drugs, etc.
Key city hospital antiasthmatic sales situation
Comprehensive database PDB drugs according to the Chinese pharmaceutical industry information center, according to data in recent 5 years, focus on urban hospitals antiasthmatic sales always maintain double-digit growth rates. In 2015, antiasthmatic in key city hospital sales of 1.971 billion yuan, 2016 years ago, three quarters of 1.766 billion yuan, is expected to still can reach 10% growth.
Figure 1 key city hospital antiasthmatic calendar year sales growth
The key city hospital sales antiasthmatic are inhaled corticosteroids (ICS), beta 2 agonists, leukotriene regulator and theophylline drugs. ICS local strong anti-inflammatory effect, less systemic adverse reactions, is the first choice for treatment of asthma medicine; Beta 2 agonists is drug of choice for treatment of acute asthma attacks, and ICS combination can be used for the treatment of asthma remission; Leukotriene regulator is the only can be used separately in addition to the ICS treatment of asthma control drugs; Theophylline drugs has diastole bronchus and airway anti-inflammatory effects, to asthma curative effect is better.
Figure 2 key city hospital classification of different antiasthmatic sales accounted for
Comprehensive database PDB drugs, according to the third quarter of 2016 years ago, hospital antiasthmatic each type of the key cities for the sales of the top five are: budesonide (31%), meng LuSi (17%) and budesonide + f ROM, mott compound (12%), doxofylline (11%) and salmeterol plus fluticasone, compound (9%), total more than 80%.
Figure 3 key city hospital antiasthmatic sales accounted for each type
Dominant in foreign company Astrazeneca outshine others
Analysis in 2015 cities key hospitals antiasthmatic each enterprise sales growth data, basic antiasthmatic market in China, were dominated by foreign companies in the sales of the top 10 half for foreign companies, total sales accounted for as high as 76.69%. Top 0, 8 companies achieved positive growth over the previous year, sales were down only glaxosmithkline and heilongjiang and huaxing pharmaceutical group co., LTD.
Figure 4 antiasthmatic each enterprise sales growth in 2015 is analyzed
The drug companies, astrazeneca outshine others, accounted for 44.12% of sales at the same time also holds 16.56% of high-speed growth. According to a former astrazeneca breathing field staff, according to the good market performance due to its abundant product line layout, in addition, GOLD guide and GINA guide product updates will astrazeneca's breath in recent years, rising to a higher position is also the important reason for the rapid growth of the share.
Astrazeneca has "letter will can protect", "Mick to shu", "Mick bao", "Connie isle atomized liquid" and "Connie isle tablet" and other five antiasthmatic products, involving budesonide, budesonide + f ROM mott compound and terbutaline and other drugs.
Domestic pharmaceutical companies, chengdu hua yu pharmaceutical co., LTD., a strong, sales proportion (3.20%) and growth (42.28%) compared to the same column respectively domestic drug firms one and all, drug companies first, main products are terbutaline sulfate injection. Southern shandong Bert pharmaceutical co., LTD., antiasthmatic sales also achieved rapid growth (35.39%), the main products are "JiShu" and "RenShu" and "level", etc.
MSD, daiichi sankyo (Shanghai) co., LTD., sichuan otsuka pharmaceutical co., LTD., Yang pharmaceutical co., LTD and five companies such as pharmaceutical co., LTD. Kaifeng connor is similar, are on the left in the middle of the above, sales account for and to achieve higher year-on-year growth.
At present domestic antiasthmatic market is headed by astrazeneca "how strong shearing section.at" pattern, various enterprises accounted for than the overall stability. A significant change in addition to astrazeneca's advantage to expand and glaxosmithkline sales percentage is declining. Glaxosmithkline also seems to have failed to fully out of the shadow of "commercial bribery" event in 2013, and after the transformation of the "price to Po quantity" model also temporarily not applied in the field of breathing.
Other companies can shake astrazeneca's advantage? Now it is difficult. Astrazeneca has set his sights on China's vast market, at the grass-roots level family atomization atomization cooperation project development and the construction of the center are shows its occupation of China breathing drug market intention and determination.
"How strong shearing section.at the antiasthmatic market in China will continue to maintain? Other enterprises can catch up? Let's wait and see. |
